Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

  title={Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders},
  author={Alline C Campos and Fabr{\'i}cio A. Moreira and Felipe V. Gomes and Elaine Aparecida Del Bel and Francisco Silveira Guimar{\~a}es},
  journal={Philosophical Transactions of the Royal Society B: Biological Sciences},
  pages={3364 - 3378}
  • A. Campos, F. Moreira, F. Guimarães
  • Published 5 December 2012
  • Biology, Psychology
  • Philosophical Transactions of the Royal Society B: Biological Sciences
Cannabidiol (CBD) is a major phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound Δ9-tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear that CBD has therapeutic potential over a wide range of non-psychiatric and psychiatric… 

Figures and Tables from this paper

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
Current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties, however, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes.
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Cannabidiol, through multi-target mechanisms, represents a valid therapeutic tool for the management of epilepsy, Alzheimer's disease, multiple sclerosis and Parkinson’s disease.
Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research
A summary of animal-based studies that support the use of CBD as an anxiolytic- and antidepressant-like compound and the putative role of epigenetic mechanisms in mediating CBD’s therapeutic outcomes are provided.
Neurological Aspects of Medical Use of Cannabidiol.
Pre-clinical evidence largely shows that CBD can produce beneficial effects in AD, PD and MS patients, but its employment for these disorders needs further confirmation from well designed clinical studies.
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
CBD is an useful and promising molecule that may help patients with a number of clinical conditions and should bring important answers in the near future and support the translation of research findings to clinical settings.
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
Neuroimaging studies have shown that acute CBD induces significant alterations in brain activity and connectivity patterns during resting state and performance of cognitive tasks in both healthy volunteers and patients with a psychiatric disorder.
Evidences for the Anti-panic Actions of Cannabidiol
CBD seems to be a promising drug for the treatment of PD, however, novel clinical trials involving patients with the PD diagnosis are clearly needed to clarify the specific mechanism of action of CBD and the safe and ideal therapeutic doses of this compound.
Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study
It is needed for conducting more preclinical investigations and upcoming clinical trials to entirely assess the CBD capability as interference for METH addiction, as growing evidence shows that CBD is a potential therapeutic agent in reducing drug reward.


A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
It is suggested that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas and the effects of this compound on human pathological anxiety and its underlying brain mechanisms.
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Cannabidiol monotherapy for treatment-resistant schizophrenia
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days.
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors
Results indicated that CBD and paroxetine decrease the number of buried marbles in the MBT through distinct pharmacological mechanisms, and suggest a potential role of drugs acting on the cannabinoid system in modulating compulsive behaviour.
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being
CBD attenuates the psychotic-like effects of cannabis over time in recreational users, and raises concerns for the harms stemming from use of varieties such as ‘skunk’ (sensimillia), which lack any CBD but currently dominate the supply of cannabis.